Krystal Biotech, Inc. KRYS
Set alert
At close · Oct 30
After hours · Oct 30, 6:54 PM ET
- YTD
- +34.78%
- 1 year
- +75.74%
- Open
- 325.83
- Prev close
- 324.55
- Mkt cap
- 9.84B
- Vol
- 330.31K
- Avg vol
- 272.35K
- EPS
- 7.98
- P/E
- 41.64
- Div yield
- 0.00%
More statistics
- Low
- 319.95
- High
- 332.63
- Forward P/E
- 37.12
- Beta
- 0.50
- Short ratio
- 9.85
- Inst. own
- 102.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 337.56
- 200-d avg
- 308.33
- 1y target
- 395.44
5D chart
Signals (141)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| RSI: Overbought | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
12 hours ago benzinga.com
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
6 days ago zacks.com
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago benzinga.com
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market…
1 week ago globenewswire.com
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2,…
2 weeks ago zacks.com
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
2 weeks ago benzinga.com
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.
-
2 weeks ago benzinga.com
Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113Substantial regression was observed in lesions not directly injected with KB113,…
2 weeks ago globenewswire.com
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113,…
2 weeks ago defenseworld.net
2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLC
Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) during the third quarter, according to the company in its most recent 13F filing with the…
3 weeks ago seekingalpha.com
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2…
3 weeks ago fool.com
Breakfast News: Week in Review
Yields hit a 24-year high as SpaceX borrows $40 billion for Nvidia chips, and more…
3 weeks ago fool.com
Breakfast News: 10 Moves to Fatten Your Nest Egg
Plan your retirement in 10 steps, SpaceX wants to buy $40B of Nvidia chips, and more…
3 weeks ago benzinga.com
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annualized basis producing an average annual return of 45.63%. Currently, Krystal Biotech has a market…
1 month ago benzinga.com
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.
-
1 month ago benzinga.com
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.
1 month ago defenseworld.net
Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS
Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities…
1 month ago defenseworld.net
Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS
Hsbc Holdings PLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The…
-
1 month ago benzinga.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market…
1 month ago zacks.com
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
1 month ago globenewswire.com
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference…
2 months ago zacks.com
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
-
2 months ago benzinga.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market…
-
2 months ago benzinga.com
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.
2 months ago 247wallst.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks,…
2 months ago benzinga.com
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market…
2 months ago zacks.com
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
3 months ago seekingalpha.com
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
3 months ago marketbeat.com
Krystal Biotech Q2 Earnings Call Highlights
Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded…
3 months ago zacks.com
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.
-
3 months ago benzinga.com
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of…
3 months ago globenewswire.com
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance…
3 months ago seekingalpha.com
Krystal Biotech: International Expansion And A Vibrant Pipeline
Krystal Biotech (KRYS) earns a STRONG BUY rating, driven by its fortress-like balance sheet, exceptional margins, and rapid Vyjuvek commercial success. KRYS's international Vyjuvek launches in Europe…
-
3 months ago benzinga.com
Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due Course
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001711279/000171127926000050/krys-20260721.htm
-
3 months ago benzinga.com
Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260720-1484359/1484359_tmhc-avns-46.pdf
-
3 months ago benzinga.com
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $364 to $396.
-
8 months ago benzinga.com
Earnings Scheduled For February 17, 2026
Earnings Scheduled For February 17, 2026
12 months ago benzinga.com
Earnings Scheduled For November 3, 2025
Earnings Scheduled For November 3, 2025
1 year ago benzinga.com
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
-
1 year ago benzinga.com
Earnings Scheduled For February 19, 2025
Earnings Scheduled For February 19, 2025
-
2 years ago benzinga.com
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
-
2 years ago benzinga.com
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
-
2 years ago benzinga.com
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023